Oxaliplatin-induced Pulmonary Fibrosis: Two Case Reports

Chun-Geun Ryu, Eun-Joo Jung, Gangmi Kim, Su Ran Kim, Dae-Yong Hwang
Department of Surgery, Colorectal Cancer Center, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea

INTRODUCTION

Oxaliplatin-based chemotherapy, including the FOLFOX regimens, has been widely used to treat colorectal cancer. However, there have been rare reports of pulmonary toxicity associated with FOLFOX regimen. Here, we report two cases of rapidly developing pulmonary fibrosis related to FOLFOX regimen usage in colorectal carcinoma.

CASE REPORTS

Case 1
A 55-year-old man had visited another hospital in May 2010 with presenting symptoms of low abdominal pain and bowel habit change for several months. He had no history of smoking, hypertension, diabetes mellitus, hepatitis or pulmonary disease. Colonoscopy showed a recto-sigmoid colon tumor. Colonoscopic biopsy revealed a moderately differentiated adenocarcinoma. On computed tomography (CT) and positive emission tomography (PET)/CT, the tumor was shown to be located on the recto-sigmoid junction, with multiple lymph-node metastases on the left supra-clavicular, para-vertebral, and para-aortic areas. Under the diagnosis of recto-sigmoid colon cancer with multiple distant metastases of lymph nodes, a laparoscopic-assisted anterior resection was performed in that hospital. The pathology result for a specimen showed a moderately differentiated adenocarcinoma that had infiltrated the pericolic adipose tissue. Lymphatic, perineural, and venous invasions were presented. Metastases of regional lymph nodes were found in 16 out of the 20 retrieved pericolic lymph nodes. The final pathologic stage was T3N2bM1, stage IV. After recovering from surgery, the patient visited our hospital for palliative treatment. FOLFOX-4 regimen (oxaliplatin with infusional 5-fluorouracil plus leucovorin) [1] was chosen and started in June 2010; targeted agents were not included because of the economic situation of the patient. Except for intermittent grade-3 neutropenia, the patient tolerated FOLFOX-4 chemotherapy well.

On the follow-up CT after the 12th cycle of chemotherapy, the multiple lymph-node metastases on the left supra-clavicular, para-vertebral, and para-aortic areas had disappeared. Two weeks following the end of 13th cycle of chemotherapy, dry cough and dyspnea developed, and the symptoms rapidly worsened. On the 28th day after the 13th cycle of chemotherapy, the patient visited our hospital due to pulmonary symptoms. Vital signs were stable with normal body temperature. On physical examination, dyspnea on exertion was presented, and inspiratory crackles were audible on both lungs. There was no chest retraction, wheezing or cyanosis. On arterial blood gas analysis (ABGA), a pH of 7.41, a PaCO2 of 27.8 mmHg and a PaO2 of 86.9 mmHg were shown in room air. The chest X-
ray and high-resolution chest computed tomography (HRCT) demonstrated parenchymal distortion, fibrosis and multiple patchy ground-glass opacities on both lungs (Fig. 1).

Under the suspicion of oxaliplatin-induced pulmonary toxicity, idiopathic pulmonary fibrosis, he was admitted and received broad-spectrum antibiotics and oral corticosteroid immediately. For the differential diagnosis with infectious pneumonia and malignant disease, bronchoscopy was performed. On bronchoscopic examination, there was no endobronchial lesion, and no other infection or malignancy was shown on bronchoscopic biopsy or bronchoalveolar lavage cytology. The bronchial washing culture was also negative. At the beginning of the treatment, the patient had felt better in terms of dyspnea. However, after two days of hospitalization, the dyspnea worsened; in spite of the medical treatment, the diffuse ground-glass opacities on chest X-ray had progressed. On the 3rd hospital day, the patient was moved into the intensive care unit (ICU) and intubated, and mechanical ventilation was started. Steroid therapy was changed to intravenous methylprednisone, but the patient showed a poor clinical course and progressively worsening radiographic findings. On the 23rd hospital day, he died due to irreversible respiratory failure and multiple organ failure.

Case 2

A 73-year-old man with hepatic flexure colon cancer was referred to the Department of Surgery for operation. He had a medical history of noninsulin-dependent diabetes mellitus without complications and no history of cigarette smoking. A right hemicolectomy was performed for colon cancer on the hepatic flexure in July 2009. Pathology showed a moderately differentiated adenocarcinoma that had infiltrated the pericolic adipose tissue. Lymphatic, perineural and venous invasions were not presented. Metastasis of a regional lymph node was found in 1 out of 34 retrieved pericolic lymph nodes. The final pathologic stage was T3N1M0, stage IIIB. A chest X-ray and chest CT before the initiation of chemotherapy showed an emphysematous lung on both upper lobes and the right middle lobe, but no pulmonary symptoms were present (Fig. 2). Adjuvant chemotherapy, including the FOLFOX-4 regimen, was started in September 2009. There were no specific changes on follow-up after every three cycles of chemotherapy, including CT and
tumor markers, during the course of the treatment.

During the 9th cycle of the FOLFOX-4 regimen, immediately after the administration of oxaliplatin, dyspnea suddenly developed on the 1st hospital day. At the time, the body temperature was 39.3°C. Pulmonary auscultation revealed inspiratory crackles in both lungs, and dyspnea on exertion was presented. Leukocytosis (23.63 × 10³/µL) with a predominance of neutrophils (94.5%) was noted on the laboratory test. C-reactive protein was elevated at 16.89 mg/dL (reference range, <0.5 mg/dL). A chest X-ray and HRCT showed ground-glass opacities in the left upper lobe and both lower lobes, and a patchy consolidation in the right middle lobe (Fig. 3). A treatment with oxygen therapy with a mask, corticosteroids and broad-spectrum antibiotics were started. Sputum and blood cultures were negative. On the test for the Swine influenza A virus, which we conducted because of a flu epidemic at the time, virus infection was negative. Based on the clinical course and imaging findings, we made a diagnosis of FOLFOX-induced interstitial pneumonitis or hypersensitivity pneumonia. He presented with progressive respiratory failure and was transferred to the ICU for mechanical ventilation on the 11th hospital day. The clinical course was unfavorable, with worsening of respiratory insufficiency, leading to the patient’s death on the 18th hospital day.

DISCUSSION

Oxaliplatin-containing regimens, including the FOLFOX regimens have become a part of the standard treatment in a high number of colorectal-cancer patients with regional lymph-node metastasis for adjuvant setting and advanced stage [2]. The major toxicity of oxaliplatin is a peripheral neuropathy. Renal, haematological and gastrointestinal toxicities are less frequent [3]. To our knowledge, oxaliplatin-induced pulmonary toxicity is rare [4], so there is no established guideline for its management.

We experienced two fatal cases with interstitial pneumonitis rapidly progressing to pulmonary fibrosis during FOLFOX-4 chemotherapy. Muneoka et al. [5] reported a case of FOLFOX-induced interstitial pneumonitis, which did not recur after the reintroduction of 5-fluorouracil/leucovorin alone. However, Yague et al. [3] reported interstitial lung disease after oxaliplatin monotherapy (85-mg/m² D1 intravenous in a 2-hour infusion every 3 weeks). Therefore, the main cause of FOLFOX-regimen-induced interstitial pneumonitis is thought to be oxaliplatin. Several case reports of oxaliplatin-induced pulmonary fibrosis have been reported. The details of those cases are shown in Table 1. The manifestations of drug-induced pulmonary toxicity are usually nonspecific, so an accurate diagnosis is difficult.

Once oxaliplatin-induced interstitial pneumonitis has occurred, cessation of oxaliplatin is mandatory [5]. High-dose corticosteroid treatment is commonly given for serious cases. However, the role of high-dose corticosteroid treatment in the management of oxaliplatin-induced interstitial pneumonitis remains unclear [5]. Of the 14 cases reported in Table 1, 13 patients were treated with high-dose corticosteroid, but 5 of the treated patients died. The median number of cycles of FOLFOX and the median dose of oxaliplatin were 6 cycles (range, 4 to 6 cycles) and 510 mg/m² (range, 340 to 780 mg/m²) in the patients who died and 13 cycles and 1,105 mg/m² in the patients who survived.

Table 1. Reported cases of oxaliplatin-induced pulmonary fibrosis

| Author                  | Sex/Age | No. of cycles | Total dose (mg/m²) | Primary lesion | Steroid treatment | Result |
|-------------------------|---------|---------------|--------------------|----------------|-------------------|--------|
| Trisolini et al. [8]    | M/60    | 7             | 910                | Rectum         | Given             | Improved |
| Gagnadoux et al. [6]    | F/60    | 8             | 680                | Colon          | None              | Improved |
| Yague et al. [3]        | F/68    | 6             | 780                | Colon          | Given             | Dead    |
| Ruiz-Casado et al. [9]  | M/67    | 11            | 1,100              | ?              | Given             | Improved |
| Pasetto and Monfardini [4] | M/74    | 6             | 510                | Sigmoid        | Given             | Dead    |
| Garrido et al. [10]     | F/30    | 6             | 510                | Rectum         | Given             | Improved |
| Arevalo et al. [2]      | M/73    | 4             | 340                | Sigmoid        | Given             | Dead    |
| Arevalo et al. [2]      | M/71    | 4             | 340                | Sigmoid        | Given             | Dead    |
| Wilcox et al. [7]       | M/71    | 6             | 510                | ?              | Given             | Dead    |
| Wilcox et al. [7]       | M/77    | 12            | 1,020              | Colon          | Given             | Improved |
| Wilcox et al. [7]       | M/69    | 6             | 510                | Colon          | Given             | Improved |
| Ohori et al. [11]       | M/69    | 10            | 850                | Colon          | Given             | Improved |
| Ohori et al. [11]       | M/72    | 11            | 935                | Colon          | Given             | Improved |
| Muneoka et al. [5]      | M/82    | 10            | 850                | Colon          | Given             | Improved |
| Case 1                  | M/55    | 13            | 1,105              | RS             | Given             | Dead    |
| Case 2                  | M/73    | 8             | 680                | HF             | Given             | Dead    |

RS, rectosigmoid; HF, hepatic flexure.
m² in case 1 and 8 cycles and 680 mg/m² in case 2, respectively. Although there were slight differences in the median numbers of cycles of FOLFOX and the median doses of oxaliplatin, some cases had a rapid and untoward course [2-4, 6, 7], similar to what occurred in our cases.

Our patients had a rapidly progressive respiratory insufficiency, needed mechanical ventilation on the 3rd day of admission in case 1 and on the 8th day of admission in case 2, were refractory to conventional high-dose corticosteroid treatment, had a poor clinical and radiographic course, and eventually died on the 23rd hospital day in case 1 and on the 18th hospital day in case 2 respectively. Even though interstitial pneumonitis is rare in patients treated with the FOLFOX regimen, we recommend careful monitoring of drug-induced pulmonary toxicity, which may occur in patients during or at the end of oxaliplatin chemotherapy.

CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was reported.

REFERENCES
1. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
2. Arevalo Lobera S, Sagastibeltza Marineloarena N, Elejoste Echeberria I, Mele Olive M, Egana Otano L, Basterretxea Badiola L, et al. Fatal pneumonitis induced by oxaliplatin. Clin Transl Oncol 2008;10:764-7.
3. Yague XH, Soy E, Merino BQ, Puig J, Fabregat MB, Colomer R. Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. Clin Transl Oncol 2005;7:515-7.
4. Passetto LM, Monfardini S. Is acute dyspnea related to oxaliplatin administration? World J Gastroenterol 2006;12:5907-8.
5. Muneoka K, Shirai Y, Sasaki M, Wakai T, Sakata J, Hatakeyama K. Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and, leucovorin (FOLFOX). Int J Clin Oncol 2009;14:457-9.
6. Gagnadoux F, Roiron C, Carrie E, Monnier-Cholley L, Lebeau B. Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. Clin Transl Oncol 2008;10:273-9.
7. Trisolini R, Lazzari Agli L, Tassinari D, Rondelli D, Cancellieri A, Patelli M, et al. Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy. Eur J Oncol 2006;10:273-9.
8. Ruiz-Casado A, Garcia MD, Racionero MA. Pulmonary toxicity of 5-fluorouracil and oxaliplatin. Clin Transl Oncol 2006;8:624.
9. Garrido M, O’Brien A, Gonzalez S, Clavero JM, Orellana E. Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report. Chest 2007;132:1997-9.
10. Ohori H, Takahashi M, Ogasawara N, Suzuki M, Miyato Y, Kato S. Two cases of interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX). Gan To Kagaku Ryoho 2009;36:295-8.